{"id":"W4389221050","doi":"10.1182/blood-2023-184531","title":"Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Nivolumab; Medicine; Ipilimumab; Internal medicine; Refractory (planetary science); Oncology; Phases of clinical research; Lymphoma; Gastroenterology; Clinical trial; CD30; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003602559,0.001668758,0.002305637,0.0003895712,0.0005061962,0.0008844369,0.0007832596,0.001304732,0.004441282],"category_scores_gemma":[0.001929761,0.0008051605,0.00180763,0.0003496695,0.001144936,0.0009996297,0.000449879,0.002770827,0.000678344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007397545,"about_ca_system_score_gemma":0.001361232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005561167,"about_ca_topic_score_gemma":0.001226009,"domain_scores_codex":[0.9986445,0.0008636503,0.00008866546,0.0001470001,0.00009599463,0.0001601675],"domain_scores_gemma":[0.9982363,0.0004727103,0.0003401799,0.0001463205,0.00008880799,0.000715717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9582919,0.01311447,0.003832326,0.0002372621,0.001259659,0.00007588654,0.00008573548,0.0005361023,0.00491972,0.00006556444,0.001185761,0.01639548],"study_design_scores_gemma":[0.8495539,0.1385948,0.008792743,0.00001768294,0.0008961459,0.00007590162,0.00002600265,0.0003591127,0.0006925117,0.0001102946,0.0008612802,0.00001951755],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907336,0.001926236,0.0005204143,0.0004202167,0.0001438803,0.00334168,0.001581376,0.00005565254,0.001276998],"genre_scores_gemma":[0.9877566,0.00127157,0.001416564,0.001040224,0.0003208857,0.004116433,0.002365839,0.0000247336,0.001687187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004441282,"threshold_uncertainty_score":0.01905239,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02715352419553314,"score_gpt":0.3111144662650398,"score_spread":0.2839609420695067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}